Hasan Avcu, MD

Hasan Avcu, MD

H. Avcu, MD earned his Doctor of Medicine degree from Istanbul University Cerrahpasa School of Medicine in Istanbul, Turkey. He has been concentrating on medical communications, thought leader management, and healthcare compliance for the last decade. He has had numerous scientific interactions, implemented educational activities, and organized advisory board meetings with thought leaders in several therapeutic areas mainly focusing on rare diseases.

All articles by Hasan Avcu, MD

PAH Six-Minute Walk Test

Could a Mobile App Boost the Utility of the Six-Minute Walk Test in PAH?

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vascular proliferation and remodeling of the small pulmonary arteries that ultimately causes right heart failure and premature death. The predominant symptom of PAH is dyspnea on exertion, with a decrease in exercise capacity.1 A variety of methods are available for the objective assessment of…

woman prepares an IV Drip

Late-Onset Pompe Disease in the Era of Enzyme Replacement Therapy

Pompe disease is a rare, multisystemic, autosomal recessive disease also known as glycogen storage disease type II. It is caused by the lack or deficiency of lysosomal acid-alpha-glucosidase (GAA), which leads to the accumulation of glycogen within lysosomes that manifests as a multisystem disorder. There was no specific treatment for Pompe disease until the first…

Alpha-1 Antitrypsin Deficiency & COVID-19

Examining the Links Between SARS-CoV-2 and Alpha-1 Antitrypsin Deficiency

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause a variety of symptoms, and people with chronic lung disease including chronic obstructive pulmonary disease (COPD), chronic liver disease especially cirrhosis, diabetes, and cardiovascular disease are among those who are more prone to develop severe infection. We now know that severe SARS-CoV-2 infection is mainly…

Next post in Features